OBJECTIVES: The aim of this study was to examine the impact of overlapping bare-metal stent (BMS) and three different formulations of drug-eluting stent (DES) on intimal hyperplasia (IH) response of patients with diabetes mellitus (DM). METHODS:Forty-nine DM patients treated with overlapping BMS (19 lesions), sirolimus-eluting stent (SES 12 lesions), paclitaxel-eluting stent (PES 8 lesions) or tacrolimus-eluting stent (TES 10 lesions) were studied. Baseline and 9-month follow-up volumetric intravascular vascular ultrasound (IVUS) and quantitative coronary angiography (QCA) analysis were performed in the entire stented segment and in the overlapped (OL) and non-overlapped (non-OL) subsegments. Clinical outcomes were evaluated at 1-year follow-up. RESULTS:Post-procedure (PO-) QCA measurements were similar in all stent groups, and between OL and non-OL subsegments in each individual type of stents. Percent IH was lower in SES and PES vs. BMS (p < 0.05). Percent IH was significantly greater in OL subsegment compared with non-OL subsegment in BMS (p < 0.05), but not in all type of DES groups. SES showed significantly less %IH compared with PES and TES in OL and non-OL subsegments. Vessel area at the OL remained unchanged from PO to FU in all type of DES and BMS groups. There were no aneurysm formation and no stent thrombosis up to 1-year follow-up. CONCLUSIONS: Overlapping BMS is associated with enhanced IH response in diabetic patients, whereas overlapping DES, particularly SES and PES, appear effective to inhibit IH without detectable late vascular adverse effects.
RCT Entities:
OBJECTIVES: The aim of this study was to examine the impact of overlapping bare-metal stent (BMS) and three different formulations of drug-eluting stent (DES) on intimal hyperplasia (IH) response of patients with diabetes mellitus (DM). METHODS: Forty-nine DMpatients treated with overlapping BMS (19 lesions), sirolimus-eluting stent (SES 12 lesions), paclitaxel-eluting stent (PES 8 lesions) or tacrolimus-eluting stent (TES 10 lesions) were studied. Baseline and 9-month follow-up volumetric intravascular vascular ultrasound (IVUS) and quantitative coronary angiography (QCA) analysis were performed in the entire stented segment and in the overlapped (OL) and non-overlapped (non-OL) subsegments. Clinical outcomes were evaluated at 1-year follow-up. RESULTS: Post-procedure (PO-) QCA measurements were similar in all stent groups, and between OL and non-OL subsegments in each individual type of stents. Percent IH was lower in SES and PES vs. BMS (p < 0.05). Percent IH was significantly greater in OL subsegment compared with non-OL subsegment in BMS (p < 0.05), but not in all type of DES groups. SES showed significantly less %IH compared with PES and TES in OL and non-OL subsegments. Vessel area at the OL remained unchanged from PO to FU in all type of DES and BMS groups. There were no aneurysm formation and no stent thrombosis up to 1-year follow-up. CONCLUSIONS: Overlapping BMS is associated with enhanced IH response in diabeticpatients, whereas overlapping DES, particularly SES and PES, appear effective to inhibit IH without detectable late vascular adverse effects.
Authors: G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock Journal: J Am Coll Cardiol Date: 2001-04 Impact factor: 24.094
Authors: Hideki Futamatsu; Manel Sabaté; Dominick J Angiolillo; Pilar Jimenez-Quevedo; Cecilia Corros; Kino Morikawa-Futamatsu; Fernando Alfonso; Julie Jiang; Pavel Cervinka; Rosana Hernandez-Antolin; Carlos Macaya; Theodore A Bass; Marco A Costa Journal: J Am Coll Cardiol Date: 2006-08-28 Impact factor: 24.094
Authors: Pilar Jiménez-Quevedo; Manel Sabaté; Dominick J Angiolillo; Marco A Costa; Fernando Alfonso; Joan Antoni Gómez-Hospital; Rosana Hernández-Antolín; Camino Bañuelos; Javier Goicolea; Francisco Fernández-Avilés; Theodore Bass; Javier Escaned; Raul Moreno; Cristina Fernández; Carlos Macaya Journal: J Am Coll Cardiol Date: 2006-05-15 Impact factor: 24.094
Authors: Dean J Kereiakes; Hong Wang; Jeffrey J Popma; Richard E Kuntz; Dennis J Donohoe; Joachim Schofer; Erick Schampaert; Bernhard Meier; Martin B Leon; Jeffrey W Moses Journal: J Am Coll Cardiol Date: 2006-06-12 Impact factor: 24.094
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: S G Ellis; M Savage; D Fischman; D S Baim; M Leon; S Goldberg; J W Hirshfeld; M W Cleman; P S Teirstein; C Walker Journal: Circulation Date: 1992-12 Impact factor: 29.690
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: Juan S Muñoz; Alexandre Abizaid; Gary S Mintz; Mariano Albertal; Andrea S Abizaid; Fausto Feres; Marinella Centemero; Rodolfo Staico; Luiz A Mattos; Ibraim Pinto; Amanda Sousa; J Eduardo Sousa Journal: Am J Cardiol Date: 2004-02-15 Impact factor: 2.778
Authors: Alexandre Abizaid; Mariano Albertal; Marco A Costa; Andrea S Abizaid; Rodolfo Staico; Fausto Feres; Luiz A Mattos; Amanda G M R Sousa; Jeffrey Moses; Nicholas Kipshidize; Gary S Roubin; Roxana Mehran; Gishel New; Martin B Leon; J Eduardo Sousa Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094